Enhanced Virus Safety of a Solvent/Detergent-Treated Anti-hemophilic Factor IX Concentrate by Dry-Heat Treatment |
Shin Jeong-Sup
(Green Cross Corp., Department of Molecular Science and Technology, College of Engineering, Ajou University)
Choi Yong-Woon (Green Cross Corp.) Sung Hark-Mo (Green Cross Corp.) Ryu Yeon-Woo (Department of Molecular Science and Technology, College of Engineering, Ajou University) Kim In-Seop (Department of Biological Sciences, College of Natural Sciences, Hannam University) |
1 | O'Connell, N. M. (2003) Factor XI deficiency-from molecular genetics to clinical management. Blood Coagul. Fibrinolysis 14 Suppl 1: S59-S64 DOI |
2 | Tabor, E. (1999) The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39: 1160-1168 DOI ScienceOn |
3 | Morgenthaler, J. J. (2000) New development in plasma fractionation and virus inactivation. Vox Sang. 78 Suppl 2: 217-221 DOI |
4 | Laub, R. and P. Strengers (2002) Parvovirus and blood products. Pathol. Biol. (Paris) 50: 339-348 DOI |
5 | Kim, I. S., Y. W. Choi, S. R. Lee, and H. M. Sung (2004) Cold ethanol fractionation and heat inactivation of hepatitis A virus during manufacture of albumin from human plasma. Biotechnol. Bioprocess Eng. 9: 57-60 |
6 | Arrighi, S., R. Rossi, M. G. Borri, V. Lesnikov, M. Lesnikova, E. Franco, M. Divizia, M. E. de Santis, and E. Bucci (1995) 'In vitro' and in animal model studies on a double virus-inactivation factor VIII concentrate. Thromb. Haemost. 74: 868-873 |
7 | Kim, I. S., Y. W. Choi, S. R. Lee, Y. Kang, K. M. Lee, D. H. Park, H. S. Woo, and S. Lee (2002) Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 7: 340-346 DOI ScienceOn |
8 | Karber, J. (1931) Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche. Arch. Exp. Pathol. Pharmakol. 162: 480-483 DOI |
9 | Murgatroyd, K. (1997) The freeze drying process. pp. 1- 58. In: P. Cameron (eds.). Good Pharmaceutical Freeze- Drying Practice. Interpharm Press, Buffalo Grove, IL, USA |
10 | Mosley, J. W. and J. Rakela (1999) Foundling viruses and transfusion medicine. Transfusion 39: 1041-1044 DOI ScienceOn |
11 | Lawlor, E., S. Graham, E. Davidson, P. L. Yap, C. Cunningham, H. Daly, and I. J. Temperley (1996) Hepatitis A transmission by factor IX concentrates. Vox Sang. 71: 126-128 DOI ScienceOn |
12 | Kim, I. S., Y. W. Choi, and S. R. Lee (2004) Optimization and validation of a virus filtration process for efficient removal of viruses from urokinase solution prepared from human urine. J. Microbiol. Biotechnol. 14: 140-147 |
13 | Burnouf, T. and M. Radosevich (2000) Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev. 14: 94-110 DOI ScienceOn |
14 | Chudy, M., I. Budek, B. Keller-Stanislawski, K. A. McCaustland, S. Neidhold, B. H. Robertson, C. M. Nubling, R. Seitz, and J. Lower (1999) A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J. Med. Virol. 57: 91-99 DOI ScienceOn |
15 | Robinson, S. M., H. Schwinn, and A. Smith (1992) Clotting factors and hepatitis A. Lancet 340: 1465 DOI ScienceOn |
16 | Dichtelmuller, H., D. Rudnick, B. Breuer, R. Kotitschke, M. Kloft, A. Darling, E. Watson, B. Flehmig, S. Lawson, and G. Frosner (1996) Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100. Biologicals 24: 125-130 DOI ScienceOn |
17 | Andrewes, C. (1989) Andrewes' Viruses of Vertebrates. pp. 120-145. Balliere Tindal, London, UK |
18 | Powell J. S., M. Bush, J. Harrison, C. Abildgaard, E. Vosburgh, A. R. Thompson, and D. Hurst (2000) Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 terminal dry heat treatment in patients with haemophilia A. Haemophilia 6: 140-149 DOI ScienceOn |
19 | Kim, I. S. (2003) Comparative inactivation of Hepatitis A virus and Murine Encephalomyocarditis virus to various inactivation processes. Kor. J. Microbiol. 39: 242-247 |
20 | Kim, I. S., Y. W. Choi, S. R. Lee, M. S. Lee, K. H. Huh, and S. Lee (2001) Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. 39: 67-73 |
21 | Boschetti, N., I. Niederhauser, C. Kempf, A. Stuhler, J. Lower, and J. Blumel (2004) Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion 44: 1079-1086 DOI ScienceOn |
22 | International Conference on Harmonisation (1998) Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability. Fed. Regist. 63: 51074-51084 |
23 | Kim, I. S., Y. W. Choi, S. R. Lee, H. S. Woo, and S. Lee (2001) Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. Biotechnol. 11: 497-503 과학기술학회마을 |
24 | Roberts, P. L. and H. Hart (2000) Comparison of the inactivation of canine and bovine parvovirus by freezedrying and dry-heat treatment in two high purity factor VIII concentrates. Biologicals 28: 185-188 DOI ScienceOn |
25 | Klein, H. G. (2005) Pathogen inactivation technology: cleansing the blood supply. J. Intern. Med. 257: 224-237 DOI ScienceOn |
26 | Robertson, B. H. and D. D. Erdman (2000) Nonenveloped viruses transmitted by blood and blood products. Dev. Biol. Standard. 102: 29-35 |
27 | Gummadi, S. N. (2003) What is the role of thermodynamics on protein stability? Biotechnol. Bioprocess Eng. 8: 9-18 DOI ScienceOn |
28 | Kim, I. S., H. G. Eo, C. W. Park, C. E. Chang, and S. Lee (2001) Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma. Biotechnol. Bioprocess Eng. 6: 25-30 DOI ScienceOn |
29 | Berkman, S. A. (1988) Infectious complications of blood transfusion. Blood Rev. 2: 206-210 DOI ScienceOn |
30 | Carpenter, J. F., M. J. Pikal, B. S. Chang, and T. W. Randolph (1997) Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res. 14: 969-975 DOI ScienceOn |